Citizens Jmp Has Lowered Expectations for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its price objective decreased by investment analysts at Citizens Jmp from $825.00 to $700.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price target would suggest a potential upside of 73.46% from the company’s current price.

AXON has been the subject of a number of other reports. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research note on Thursday. UBS Group dropped their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday. Weiss Ratings cut shares of Axon Enterprise from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Needham & Company LLC dropped their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Morgan Stanley set a $600.00 price target on shares of Axon Enterprise in a research note on Thursday. Sixteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $403.54 on Thursday. Axon Enterprise has a 52 week low of $339.01 and a 52 week high of $885.91. The stock has a market capitalization of $32.51 billion, a P/E ratio of 162.06, a PEG ratio of 9.11 and a beta of 1.44. The firm has a fifty day simple moving average of $451.93 and a two-hundred day simple moving average of $527.52. The company has a quick ratio of 2.29, a current ratio of 2.27 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. During the same period last year, the company posted $1.47 EPS. The business’s revenue was up 33.7% on a year-over-year basis. On average, analysts expect that Axon Enterprise will post 1.41 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the transaction, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Erika Nardini sold 198 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the sale, the director directly owned 1,946 shares of the company’s stock, valued at approximately $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,855 shares of company stock worth $7,109,828 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several large investors have recently added to or reduced their stakes in AXON. Creative Financial Designs Inc. ADV purchased a new stake in Axon Enterprise in the 4th quarter valued at about $28,000. Stone House Investment Management LLC purchased a new stake in Axon Enterprise in the 3rd quarter valued at about $29,000. New Millennium Group LLC purchased a new stake in Axon Enterprise in the 3rd quarter valued at about $29,000. Sound Income Strategies LLC boosted its position in Axon Enterprise by 550.0% in the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 44 shares during the period. Finally, Camelot Portfolios LLC purchased a new stake in Axon Enterprise in the 4th quarter valued at about $30,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported Q1 revenue of about $807 million, up 33.7% year over year, with EPS of $1.61 topping consensus by a penny and management lifting its 2026 revenue growth outlook to 30%-32% while targeting roughly $450 million in free cash flow. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analysts largely remained constructive, with multiple firms reiterating bullish ratings and new/raised price targets, citing strong ARR growth, AI-driven demand, and durable growth prospects. Axon Earns Buy Rating on Robust ARR Growth, AI-Driven Demand, and Underappreciated Profitability
• Positive Sentiment: Baltimore approved a $153 million police-equipment contract, highlighting continued public-safety spending that could benefit Axon’s body cameras, Tasers, and related software ecosystem. Baltimore police to get upgraded body-worn cameras, Tasers after city approves $153 million contract
• Neutral Sentiment: Some coverage noted that Q1 earnings slightly missed estimates and tariff-related margin pressure offset part of the strong revenue growth, creating a mixed read on near-term profitability. AXON Q1 Earnings Miss Estimates on Tariff-Driven Margins
• Negative Sentiment: The stock also faced some valuation pressure from mixed analyst target moves, including at least one notable cut even as ratings stayed positive. Axon Enterprise price target lowered by Citizens JMP

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.